IRF9 Antibody - #DF8179

(1)   (1)  
製品: IRF9 Antibody
カタログ: DF8179
タンパク質の説明: Rabbit polyclonal antibody to IRF9
アプリケーション: WB
Cited expt.: WB
反応性: Human, Mouse, Rat
予測: Horse, Dog
分子量: 48 kDa; 44kD(Calculated).
ユニプロット: Q00978
RRID: AB_2841496

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:1000-3000
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Horse(92%), Dog(92%)
クローナリティ:
Polyclonal
特異性:
IRF9 Antibody detects endogenous levels of total IRF9.
RRID:
AB_2841496
引用形式: Affinity Biosciences Cat# DF8179, RRID:AB_2841496.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

IFN alpha responsive transcription factor subunit; IFN-alpha-responsive transcription factor subunit; Interferon regulatory factor 9; interferon stimulated transcription factor 3; Interferon-stimulated gene factor 3 gamma; interferon-stimulated transcription factor 3, gamma 48kDa; IRF 9; IRF-9; Irf9; IRF9_HUMAN; ISGF 3 gamma; ISGF-3 gamma; ISGF3; ISGF3 p48 subunit; ISGF3G; OTTHUMP00000164692; OTTHUMP00000164693; p48; Transcriptional regulator ISGF3 subunit gamma;

免疫原

免疫原:

A synthesized peptide derived from human IRF9, corresponding to a region within the internal amino acids.

Uniprot:

Q00978(IRF9_HUMAN) >>Visit HPA database.

遺伝子(ID):
IRF9(10379)
タンパク質配列:
MASGRARCTRKLRNWVVEQVESGQFPGVCWDDTAKTMFRIPWKHAGKQDFREDQDAAFFKAWAIFKGKYKEGDTGGPAVWKTRLRCALNKSSEFKEVPERGRMDVAEPYKVYQLLPPGIVSGQPGTQKVPSKRQHSSVSSERKEEEDAMQNCTLSPSVLQDSLNNEEEGASGGAVHSDIGSSSSSSSPEPQEVTDTTEAPFQGDQRSLEFLLPPEPDYSLLLTFIYNGRVVGEAQVQSLDCRLVAEPSGSESSMEQVLFPKPGPLEPTQRLLSQLERGILVASNPRGLFVQRLCPIPISWNAPQAPPGPGPHLLPSNECVELFRTAYFCRDLVRYFQGLGPPPKFQVTLNFWEESHGSSHTPQNLITVKMEQAFARYLLEQTPEQQAAILSLV

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
92
Dog
92
Bovine
75
Rabbit
75
Pig
67
Sheep
58
Zebrafish
50
Xenopus
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

機能:

Transcription factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. IRF9/ISGF3G associates with the phosphorylated STAT1:STAT2 dimer to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state.

細胞の位置付け:

Cytoplasm. Nucleus.
Note: Translocated into the nucleus upon activation by IFN-alpha/beta.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
タンパク質ファミリー:

Belongs to the IRF family.

研究領域

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

参考文献

1). Chemotherapy-induced macrophage CXCL7 expression drives tumor chemoresistance via the STAT1/PHGDH-serine metabolism axis and SAM paracrine feedback to M2 polarization. Cell death & disease, 2025 (PubMed: 40368902) [IF=8.1]

Application: WB    Species: human    Sample:

Fig. 5: STAT1 mediates CXCL7-induced PHGDH transcription and chemotherapy resistance. A GSEA analysis illustrating the correlation between CXCL7 and the interferon signaling pathway. B Predicted STAT1-binding sequences in the PHGDH promoter region using the JASPAR database. C The correlationship between STAT1 and PHGDH mRNA expression. D ChIP-qPCR results showing STAT1 enrichment at the PHGDH promoter. E Luciferase reporter assay results demonstrating PHGDH promoter activity in response to CXCL7 treatment with or without JAK1 inhibition. F Effects of JAK1 inhibition on PHGDH mRNA expression following CXCL7 treatment. G Western blot analysis of p-JAK1, JAK1, p-STAT1, STAT1, PHGDH, and IRF9 protein levels in cells treated with CXCL7 with or without JAK1 inhibition. H Cell viability assessment for cell treatment with CXCL7, following PHGDH inhibition or JAK1 inhibition. I Effects of PHGDH or JAK1 inhibition on tumor growth in mice with CXCL7-overexpressing cell. J IHC analysis of p-STAT1, PHGDH, and CD206 expression, along with TUNEL staining for apoptosis, in CXCL7-overexpressing tumors treated with PHGDH or JAK1 inhibitor (scale bar for IHC, 50 μm; scale bar for TUNEL, 10 μm). All data are presented as mean ± SD. *P 

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.